Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Climb Bio, Inc. (CLYM)

Capricor Therapeutics, Inc. and Climb Bio, Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and Climb Bio, Inc. are of similar size ($509.5M and $500.0M). Across the 9 metrics below, Climb Bio, Inc. leads on 7 and Capricor Therapeutics, Inc. on 2.

Valuation

Metric CAPR CLYM Biotechnology median
P/E n/m n/m 10.60
P/S 23.51 n/m 9.40
P/B 2.13 3.27 2.13
Price to free cash flow 4.00 n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 13.47 n/m 9.02
Earnings yield (27.10%) (8.07%) (32.88%)
Free cash flow yield 25.00% (6.79%) (23.13%)

Profitability

Metric CAPR CLYM Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (27.10%) (51.96%)
Return on assets (51.53%) (26.27%) (46.06%)
Return on invested capital (1,019.73%) (71.73%) 0.00%

Growth

Metric CAPR CLYM Biotechnology median
Revenue growth (TTM) (11.55%) — 6.76%
EPS growth (last fiscal year) (96.52%) 42.48% 29.88%
Revenue growth, 5-year CAGR 85.83% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR CLYM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 31.45 4.97
Net debt to EBITDA 2.99 1.44 1.01

Dividend

Metric CAPR CLYM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAPR CLYM Biotechnology median
Market cap 500.00m 509.46m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack